Poltreg S.A.

PTG

PLPLTRG00038

Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 11:55:45 2024-05-16 am EDT			5-day change	1st Jan Change
47 ^PLN	-4.86%		-4.08%	-5.62%

Apr. 18	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 11	Poltreg S.A. Receives CGMP Certification to Produce Cell Therapies At Its State-Of-The-Art Manufacturing Site in Poland	CI

Poltreg S.A. has completed an IPO in the amount of PLN 125.086575 million.

November 08, 2021 at 12:00 am EST

Poltreg S.A. has completed an IPO in the amount of PLN 125.086575 million. Security Name: M Shares Security Type: Common Stock Securities Offered: 1,667,821 PriceRange: PLN 75

Latest news about Poltreg S.A.

Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Poltreg S.A. Receives CGMP Certification to Produce Cell Therapies At Its State-Of-The-Art Manufacturing Site in Poland	Mar. 11	CI
Poltreg S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Poltreg S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-06	CI
Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Poltreg S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Poltreg S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-31	CI
Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-27	CI
Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-27	CI
Poltreg S.A. has completed an IPO in the amount of PLN 125.086575 million.	21-11-08	CI
Poltreg S.A. has filed an IPO in the amount of PLN 130 million.	21-10-14	CI

Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

47 PLN

Average target price

68.2 PLN

Spread / Average Target

+45.11%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
POLTREG S.A.	-5.62%	58.79M
MODERNA, INC.	+33.68%	49.46B
IQVIA HOLDINGS INC.	+1.56%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.69%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.04%	18.64B
BIO-TECHNE CORPORATION	+7.39%	13.16B
MEDPACE HOLDINGS, INC.	+28.64%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.85%	12.1B

Other Biotechnology & Medical Research

Poltreg S.A.

Equities

PTG

PLPLTRG00038

Biotechnology & Medical Research

Poltreg S.A. has completed an IPO in the amount of PLN 125.086575 million.

Latest news about Poltreg S.A.

Chart Poltreg S.A.

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research